CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Broker consensus is “Hold”: Of six analysts, one recommends selling, three rate the stock a hold, one recommends buying and one gives a strong buy. The average 12-month price target is $6.90.
• CVRx shares fell 54.2% to $2.72, near their 52-week low of $2.68, while the company reported a $0.53-per-share quarterly loss and approximately negative 89% net margin.
• Revenue slightly beat expectations at $15.71 million, but the outlook weakened: Third-quarter revenue was guided to $13.5 million-$14.5 million, and full-year 2026 revenue guidance was cut to $58 million-$60 million versus analysts’ $65.4 million consensus.

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.90.

A number of research analysts have weighed in on the company. Wall Street Zen raised CVRx from a "sell" rating to a "hold" rating in a report on Saturday, June 27th. Lake Street Capital cut shares of CVRx from a "buy" rating to a "hold" rating and set a $3.50 target price on the stock. in a research note on Friday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of CVRx in a report on Monday. Canaccord Genuity Group reiterated a "buy" rating and issued a $10.00 price target on shares of CVRx in a research note on Tuesday, April 14th. Finally, Craig Hallum lowered CVRx from a "buy" rating to a "hold" rating and set a $4.00 price objective for the company. in a research report on Friday.

CVRx Stock Down 54.2%

CVRx stock traded down $3.22 during trading on Friday, hitting $2.72. 2,057,584 shares of the company were exchanged, compared to its average volume of 331,402. The company has a market capitalization of $72.22 million, a P/E ratio of -1.34 and a beta of 0.81. The business's 50 day moving average is $5.26 and its 200 day moving average is $6.52. CVRx has a 52 week low of $2.68 and a 52 week high of $11.30. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01.

CVRx (NASDAQ:CVRX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.01). The company had revenue of $15.71 million during the quarter, compared to analysts' expectations of $15.55 million. CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%. Analysts predict that CVRx will post -1.89 earnings per share for the current year.

Hedge Funds Weigh In On CVRx

A number of large investors have recently added to or reduced their stakes in CVRX. Larson Financial Group LLC grew its stake in shares of CVRx by 155.6% during the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company's stock worth $39,000 after acquiring an additional 3,303 shares during the last quarter. R Squared Ltd acquired a new stake in CVRx during the 4th quarter worth about $74,000. Aaron Wealth Advisors LLC purchased a new position in CVRx during the first quarter valued at approximately $101,000. Virtu Financial LLC acquired a new position in shares of CVRx in the 4th quarter valued at $79,000. Finally, Corient Private Wealth LLC purchased a new stake in CVRx during the fourth quarter worth $81,000. 75.27% of the stock is currently owned by institutional investors.

CVRx News Roundup

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, ahead of the $15.55 million analyst consensus. The company’s loss of $0.53 per share was also an improvement from the $0.57-per-share loss recorded a year earlier. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The revenue beat suggests demand for CVRx’s neuromodulation devices remained somewhat better than expected during the quarter, potentially supporting the initial positive stock reaction. CVRx Reports Q2 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management’s operating update and detailed quarterly metrics provide additional information for investors assessing procedure volumes, commercial execution and adoption of the company’s cardiovascular therapies. Compared to Estimates, CVRx Q2 Earnings: A Look at Key Metrics
• Negative Sentiment: CVRx’s $0.53-per-share loss was slightly worse than the $0.52 consensus estimate, underscoring that the company remains unprofitable. Its reported net margin was approximately negative 89%. CVRx Earnings Results
• Negative Sentiment: Management guided third-quarter revenue to $13.5 million-$14.5 million, well below the $16.9 million analyst estimate, and reduced full-year 2026 revenue guidance to $58 million-$60 million versus the $65.4 million consensus. The outlook implies slowing growth and could pressure the stock after the initial earnings reaction.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company's flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body's natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source